**Abstract**

Nicotine dependence is one of the most significant public health problems worldwide, and much more common in schizophrenia patients (smoking rates in schizophrenia range from 45 to 88%, compared to \< 20% in the general population). While many studies have revealed nicotinic acetylcholine receptor (nAChR) subunits are associated with nicotine dependence both genetically and functionally, genome-wide association studies and candidate gene analysis for nicotine dependence have identified Cadherin13 (CDH13) as one of susceptibility genes other than nAChR genes. In addition, we previously reported that genetic variants of CDH13 promoter are associated with schizophrenia for the first time. However, no previous work has investigated the function of CDH13 in nicotine dependence or the genetic association of CDH13 with high smoking rates in schizophrenia. In this study, we attempted to evaluate the function of CDH13 in nicotine dependence and whether a genetic variant of CDH13 contributes to smoking status in schizophrenia patients.

Mouse neural progenitor cells (mNPCs) were prepared from hippocampus of neonatal mice. In mNPCs treated with nicotine, CDH13 mRNA expression were significantly decreased (p=0.040). In mNPCs with knockdown of CDH13 using siRNA technique, neuronal acetylcholine receptor subunit alpha-3 (CHRNA3) mRNA expression were significantly increased (p=0.004), while other nAChR mRNA expression were not changed. Furthermore, five tag single nucleotide polymorphisms (SNPs) in CDH13 promoter were genotyped in 150 male schizophrenia patients (114 current/past smokers and 36 never smokers). rs7193788 of the five SNPs was significantly associated with smoking experience in schizophrenia patients (p=0.027).

Our study suggests that CDH13 reduction may contribute to nicotine dependence via upregulation of CHRNA3 and CDH13 may be associated with genetic susceptibility to nicotine dependence in schizophrenia.

This study was carried out in strict accordance with the Guidelines for Animal experiments and the Ethical Committee for Genetic Studies of Kobe University Graduate School of Medicine.
